Tybourne Capital Management HK Ltd. Has $31.56 Million Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Tybourne Capital Management HK Ltd. lessened its stake in Bicycle Therapeutics plc (NASDAQ:BCYC) by 7.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,394,535 shares of the company’s stock after selling 115,178 shares during the period. Bicycle Therapeutics comprises about 8.8% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 6th biggest position. Tybourne Capital Management HK Ltd. owned 2.93% of Bicycle Therapeutics worth $31,558,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in BCYC. FMR LLC acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter worth approximately $3,406,000. The Manufacturers Life Insurance Company raised its stake in Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock worth $2,935,000 after buying an additional 32,313 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in Bicycle Therapeutics by 21.5% during the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after buying an additional 327,089 shares during the last quarter. L & S Advisors Inc lifted its holdings in Bicycle Therapeutics by 2.4% in the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after buying an additional 1,400 shares during the period. Finally, Crossmark Global Holdings Inc. bought a new stake in Bicycle Therapeutics during the third quarter valued at $257,000. Institutional investors own 86.15% of the company’s stock.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,212 shares of the company’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now owns 380,864 shares in the company, valued at $8,478,032.64. This represents a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the sale, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,840 shares of company stock worth $259,128. Insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Trading Down 0.2 %

NASDAQ BCYC opened at $20.35 on Thursday. The company has a market cap of $967.64 million, a P/E ratio of -6.19 and a beta of 0.89. The company has a fifty day simple moving average of $23.71 and a 200 day simple moving average of $22.97. Bicycle Therapeutics plc has a 12-month low of $13.47 and a 12-month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same period last year, the company earned ($1.26) earnings per share. The business’s revenue was down 50.0% on a year-over-year basis. Sell-side analysts predict that Bicycle Therapeutics plc will post -3.07 EPS for the current year.

Wall Street Analyst Weigh In

BCYC has been the subject of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, September 16th. B. Riley downgraded Bicycle Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $33.00 to $28.00 in a report on Wednesday, August 7th. Stephens initiated coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.